Alkermes stock maintains Buy rating at Stifel after narcolepsy drug results

Investing.comWednesday, November 12, 2025 at 4:39:48 PM
Alkermes stock maintains Buy rating at Stifel after narcolepsy drug results
Alkermes has maintained a 'Buy' rating from Stifel following positive results from its narcolepsy drug. This endorsement is significant as it reflects confidence in the company's product and its potential impact on the market for narcolepsy treatments. The stock rating suggests that analysts believe Alkermes is a worthwhile investment, which could influence investor sentiment and market performance.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Stifel raises Neumora Therapeutics stock price target to $3 from $2
PositiveFinancial Markets
Stifel has raised its price target for Neumora Therapeutics' stock from $2 to $3. This adjustment reflects a positive outlook on the company's performance and potential growth in the market. The change was announced on November 17, 2025, indicating Stifel's confidence in Neumora's future prospects.
Truist Securities raises Alkermes stock price target to $55 on positive trial data
PositiveFinancial Markets
Truist Securities has raised its price target for Alkermes stock to $55 following positive trial data. This adjustment reflects the firm's confidence in the company's future performance based on recent developments in its clinical trials. The new target indicates a bullish outlook for Alkermes in the market.